All In MedTech

Device Trial Radar · NCT03111420

Study of AggreGuide A-100 (ADP) Assay

Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs

Last checked: Nov 20, 2026Latest source record: Feb 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Jan 9, 2017

Primary completion

Jun 2018

Study completion Jun 2018

Sponsor

Lead sponsor
Aggredyne, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 12, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 74 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.

Conditions

  • Risk Factor, Cardiovascular
  • Platelet Dysfunction Due to Drugs

Interventions

  • P2Y12 inhibitorDrug

    Administration of P2Y12 inhibitor antiplatelet therapy

  • Platelet function testDevice

    Blood is drawn for testing of platelet aggregation activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Platelet Activity Index (PAI)Time frame: Baseline, day 1, day 7

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.